International Session（Symposium）2(JSGS・JSGE・JGES)
Fri. November 3rd   14:00 - 17:00   Room 11: Portopia Hotel South Wing Topaz
IS-S2-1_S
 Conversion surgery for Esophageal Squamous Cell Carcinoma with distant metastasis -Multicenter exploratory study-
Satoru Matsuda1, Hiroya Takeuchi2, Yuko Kitagawa1
1Department of Surgery, Keio University School of Medicine, 2Department of Surgery, Hamamatsu University School of Medicine
Background: The increased efficacy of multimodality treatment allows for the consideration of conversion therapy for metastatic esophageal squamous cell carcinoma (ESCC). We previously reported the consensus of conversion therapy for ESCC. In order to explore the safety and efficacy of conversion surgery for metastatic ESCC, we conducted multicenter retrospective study.
Methods: Patients with ESCC who underwent esophagectomy at 3 authorized institutes were retrospectively reviewed. Patients with distant metastasis who underwent conversion surgery with curative intent were included. Patients' characteristics, surgical outcomes, and survival were analyzed.
Results: Twenty patients were enrolled. In terms of location of distant metastasis, 16a2b1/Stomach/Adrenal gland/Liver was 9/1/1/1, respectively. Of 12 patients, 9 patients received DCF therapy as an initial treatment while 3 received CF. R0 resection was achieved in all patients. Three-year recurrence free survival (RFS) and overall (OS) rate was 42%/58% in entire cohort. When pathological Grade 2 and 3 weas defined as responder, pathological responder (R) showed significantly longer RFS and OS than non-responder (NR) (3-year RFS, R 100%, NR 13%; 3-year OS, R 100%, NR 38%).
Conclusion: Conversion therapy was safely conducted with feasible survival outcomes especially patients who responded to initial treatment.
Index Term 1: Esophageal cancer
Index Term 2: Conversion surgery
Page Top